Table 1. Characteristics of the patients at baseline.
| Characteristics | N=16 |
|---|---|
| Age, median [range] | 66 [42–73] |
| Sex, n (%) | |
| Male | 7 (43.8) |
| Female | 9 (56.3) |
| Ethnicity, n (%) | |
| Caucasian | 15 (93.8) |
| African American | 1 (6.3) |
| ECOG PS, n (%) | |
| 0 | 1 (6.3) |
| 1 | 15 (93.8) |
| 2 | 0 |
| Prior systemic therapy, n (%) | |
| Gemcitabine | 1 (6.3) |
| Gemcitabine/nab-pac* | 6 (37.0) |
| Gemcitabine/nab-pac/indoximod | 5 (31.0) |
| Gemcitabine/nab-pac/radiation | 1 (6.3) |
| Gemcitabine/nab-pac/VS4718 | 1 (6.3) |
| Gemcitabine/nab-pac followed by 5-FU/XRT** | 1 (6.3) |
| CA19-9, mean [min, max] | 1,255 [1–8,803] |
Percentages might not total 100% due to rounding. *Nab-pac, nanoparticle albumin-bound paclitaxel; **XRT, radiation.